[go: up one dir, main page]

WO2009035534A3 - Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) - Google Patents

Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) Download PDF

Info

Publication number
WO2009035534A3
WO2009035534A3 PCT/US2008/010413 US2008010413W WO2009035534A3 WO 2009035534 A3 WO2009035534 A3 WO 2009035534A3 US 2008010413 W US2008010413 W US 2008010413W WO 2009035534 A3 WO2009035534 A3 WO 2009035534A3
Authority
WO
WIPO (PCT)
Prior art keywords
hif
eye disease
systematic
treatment
inducible factor
Prior art date
Application number
PCT/US2008/010413
Other languages
French (fr)
Other versions
WO2009035534A2 (en
Inventor
Jonathan E Sears
George B Hoppe
Quteba Ebrahem
Original Assignee
Cleveland Clinic Foundation
Jonathan E Sears
George B Hoppe
Quteba Ebrahem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation, Jonathan E Sears, George B Hoppe, Quteba Ebrahem filed Critical Cleveland Clinic Foundation
Publication of WO2009035534A2 publication Critical patent/WO2009035534A2/en
Publication of WO2009035534A3 publication Critical patent/WO2009035534A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention consists of a method of treating a subject with an ischemic eye disease associated with the down-regulation of HIF comprising administering to the subject an effective amount of a compound that induces HIF activity and/or induces EPO activity to induce and maintain growth or normal retinal blood vessels in the early stage of the disease.
PCT/US2008/010413 2007-09-07 2008-09-05 Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) WO2009035534A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96790107P 2007-09-07 2007-09-07
US60/967,901 2007-09-07

Publications (2)

Publication Number Publication Date
WO2009035534A2 WO2009035534A2 (en) 2009-03-19
WO2009035534A3 true WO2009035534A3 (en) 2009-05-07

Family

ID=40134829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010413 WO2009035534A2 (en) 2007-09-07 2008-09-05 Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)

Country Status (1)

Country Link
WO (1) WO2009035534A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153197A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
EA025180B1 (en) * 2011-03-21 2016-11-30 Виволюкс Аб Treatment of solid tumours
NO2686520T3 (en) 2011-06-06 2018-03-17
PT2900667T (en) * 2012-09-21 2019-09-04 Vivolux Ab Means and method for treating solid tumours
WO2014200773A2 (en) 2013-06-13 2014-12-18 Akebia Therapeutics , Inc. Compositions and methods for treating anemia
EP3096617A4 (en) * 2014-01-23 2017-09-13 Akebia Therapeutics Inc. Compositions and methods for treating ocular diseases
BR112017015852A2 (en) 2015-01-23 2018-03-27 Akebia Therapeutics Inc crystal form, hemichalic salt, hemicalic salt dihydrate, hydrous monosodium salt, monohydrate bisodium salt, anhydrous monosodium salt and method for preparing compound 1
TWI881714B (en) 2015-04-01 2025-04-21 美商阿克比治療有限公司 Compositions and methods for treating anemia
DK3390403T3 (en) * 2015-12-18 2022-08-29 Vivolux Ab PHARMACOLOGICAL COMPOSITION COMPRISING INDOLE DERIVATIVES, METHOD OF PREPARATION AND USE THEREOF
GB201720320D0 (en) 2017-12-06 2018-01-17 Univ Of Sussex Tissue repair
WO2019136466A1 (en) 2018-01-08 2019-07-11 Yale University Compounds and methods for treating or preventing anterior segment ocular disorders and/or retinal degenerations
KR20210006967A (en) 2018-05-09 2021-01-19 아케비아 테라퓨틱스 인코포레이티드 Method for Producing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US20230301984A1 (en) * 2020-07-02 2023-09-28 The Usa, As Represented By The Secretary, Department Of Health And Human Services Cyclic compounds for use in treating retinal degeneration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089809A1 (en) * 2001-05-04 2002-11-14 The Procter & Gamble Company Medicinal uses of hydrazones and hydrazines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089809A1 (en) * 2001-05-04 2002-11-14 The Procter & Gamble Company Medicinal uses of hydrazones and hydrazines
US20030092716A1 (en) * 2001-05-04 2003-05-15 The Procter & Gamble Company Medicinal uses of hydrazones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JUNK A K ET AL: "Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, vol. 99, no. 16, 1 January 2002 (2002-01-01), pages 10659 - 10664, XP008090830, ISSN: 0027-8424 *
NAGLE DALE G ET AL: "Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1).", CURRENT PHARMACEUTICAL DESIGN 2006, vol. 12, no. 21, 2006, pages 2673 - 2688, XP002509125, ISSN: 1381-6128 *
WHITLOCK N ANDREW ET AL: "Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE MAR 2005, vol. 46, no. 3, March 2005 (2005-03-01), pages 1092 - 1098, XP002509127, ISSN: 0146-0404 *
ZHU Y ET AL: "DESFERROXAMINE PRETREATMENT PROMOTES PROLONGED RETINAL ISCHEMIC TOLERANCE IN MICE: A NEW MODEL OF CHEMICAL PRECONDITIONING IN RETINA", ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2003, 2003, & ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY; FORT LAUDERDALE, FL, USA; MAY 04-08, 2003, pages Abstract No. 2925, XP002509126 *

Also Published As

Publication number Publication date
WO2009035534A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009035534A3 (en) Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
EA201300522A1 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
WO2007120936A3 (en) Use.of vildagliptin for the treatment of diabetes
EP3773880A4 (en) Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods
WO2011020319A8 (en) Fusion protein regulating plasma glucose and lipid, its preparation method and use
WO2008149802A1 (en) Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient
WO2009055331A3 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
EA200900896A1 (en) HETEROCYCLIC COMPOUND RECEPTOR-AGONISTS (VARIANTS) PHARMACEUTICAL COMPOSITION ON THEIR BASIS METHOD FOR TREATING DIABETES AND METABOLIC DISORDERS, a method of stimulating insulin production (VARIANTS) AND METHODS FOR REDUCING GLUCOSE LEVEL IN BLOOD AND TRIGLYCERIDES BY COMPOUNDS LISTED
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2007128817A3 (en) Insulin derivative
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
TW200740804A (en) Glucokinase activators
WO2007117381A3 (en) 2 -aminopyridine analogs as glucokinase activators
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
EA201101187A1 (en) ANTI-DIABETIC MEDICINES CONTAINING DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONAL IN COMBINATION WITH OTHER ANTI-DIABETIC MEANS
WO2005107730A3 (en) Cysteamines for treating complications of hypercholesterolemia and diabetes
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2010042886A3 (en) Pyrones for the treatment of metabolic disorders
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
EA200800338A1 (en) PREVENTION AND TREATMENT OF OPHTHALMOLOGICAL COMPLICATIONS OF DIABETES
BRPI0520258A2 (en) use of a pharmaceutical composition, method for preparing a pharmaceutical composition, and use of an effective amount of eslicarbazepine acetate
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2007005774A3 (en) Novel derivatives of amino acids for treatment of obesity and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831068

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831068

Country of ref document: EP

Kind code of ref document: A2